( Posted by Desinie Smith)
By Thomas Gryta Of DOW JONES NEWSWIRES
NEW
YORK (Dow Jones)--Biogen Idec Inc. (BIIB) disclosed seven more cases of
a rare brain infection in multiple sclerosis patients using Tysabri,
which it sells with Elan Corp. (ELN), bringing the total number of cases
to 42 as of last Wednesday.
Another patient with the infection
has died, bringing the total deaths to nine in patients that have
developed progressive multifocal leukoencephalopathy, or PML, according
to the Cambridge, Mass., biotech company.
Read the rest of the article in the Wall Street Journal by clicking here.
